Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC decreased its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 0.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 48,391 shares of the company’s stock after selling 454 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Dyne Therapeutics were worth $1,738,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Nisa Investment Advisors LLC increased its holdings in shares of Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after acquiring an additional 669 shares during the last quarter. US Bancorp DE boosted its holdings in Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares during the period. Values First Advisors Inc. bought a new stake in Dyne Therapeutics during the third quarter valued at $62,000. KBC Group NV lifted its position in shares of Dyne Therapeutics by 53.4% in the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after buying an additional 751 shares during the last quarter. Finally, Amalgamated Bank boosted its holdings in shares of Dyne Therapeutics by 39.9% in the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock valued at $99,000 after buying an additional 796 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Insider Buying and Selling at Dyne Therapeutics

In related news, SVP Richard William Scalzo sold 1,390 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total value of $48,024.50. Following the completion of the sale, the senior vice president now directly owns 98,568 shares in the company, valued at approximately $3,405,524.40. The trade was a 1.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO John Cox acquired 32,000 shares of the company’s stock in a transaction on Wednesday, September 4th. The stock was bought at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the acquisition, the chief executive officer now directly owns 8,000 shares in the company, valued at approximately $264,320. This represents a -133.33 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 176,257 shares of company stock valued at $6,193,718. 20.77% of the stock is currently owned by corporate insiders.

Dyne Therapeutics Stock Performance

NASDAQ:DYN opened at $29.69 on Monday. The firm’s 50-day moving average is $32.16 and its 200-day moving average is $35.37. Dyne Therapeutics, Inc. has a 52-week low of $10.12 and a 52-week high of $47.45. The company has a market cap of $3.02 billion, a price-to-earnings ratio of -8.34 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). Equities analysts predict that Dyne Therapeutics, Inc. will post -3.39 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on DYN shares. Oppenheimer reissued an “outperform” rating and issued a $55.00 target price on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. Chardan Capital restated a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. Piper Sandler reaffirmed an “overweight” rating and issued a $53.00 target price on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Guggenheim boosted their price target on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, August 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $51.40.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.